ClinicalTrials.gg
CompletedNCT03399526Updated Jan 16, 2018

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

A Phase 1 interventional study of Mapracorat (ZK 245186, BAY 86-5319) and Prednicarbate 0.25% ointment in Psoriasis, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Feb 2013, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.

Enrollment
226th of 260
24 · median 196
Started
2013
with 13 others
Phase 1
26 of 299
none open now
Registered
186th of 299
by date

Among the 299 studies in Psoriasis with a site in Germany, this one is the 226th largest by enrollment of the 260 interventional ones that give a count, is one of 14 that started in 2013, is one of 26 in phase 1, and was the 186th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Psoriasis with a site in Germany, or all of them as a file.
02

Study summary

Evaluation of efficacy and safety of Mapracorat 0.1% ointment and 4 comparator ointments in male and female subjects 18 to 65 years with stable plaque-type psoriasis treated once daily 6 days a week for a maximum of 4 weeks.

Primary objective was to compare the efficacy of all test compounds by measurement of psoriatic infiltrate thickness (PIT) with 20 MHz B mode ultrasound.

Secondary objectives were to assess safety of all test compounds by measurement of the atrophogenic potential on non-lesional skin with 20 MHz B mode ultrasound, to assess the efficacy of all test compounds by measurement of intensity of erythema measured by chromametry, to assess the efficacy of all test compounds by visual assessment of the skin in the test fields using a 5-point score, to assess the safety of all test compounds by visual assessments of formation of teleangiectasia using a 5-point score, to assess the safety of all test compounds by visual assessment of atrophy using a 5-point score, to assess the safety of all test compounds by visual assessment of local tolerability using a 5-point score, to visualize the therapeutic index given by PIT versus non lesional skin thickness.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 18 to 65 years of age with stable plaque-type psoriasis, plaques of adequate size to allow for evaluation of 5 test fields, on comparable body area; thickness of the echo-lucent band under the entry echo as assessed by ultrasound of at least 200 μm

Exclusion criteria

Exclusion Criteria:

  • Positive testing in urine drug screening
  • Pregnancy or lactation
  • A history of relevant diseases, especially-incompletely cured pre-existing diseases for which it could have been assumed that the absorption, distribution, excretion and effect of the study drugs would not be normal
  • Volunteers with severe kidney or liver disease
  • Volunteers with concurrent/acute viral infections in the test field areas (e.g. herpes simplex, varicella) or other specific skin alterations (skin tuberculosis, syphilitic skin lesions)
  • Severe disease within the last 4 weeks prior to the first study drug administration
  • Volunteers with known reaction when applying adhesive bandages
  • Volunteers who were treated with any systemic therapy for psoriasis (e.g. methotrexate, cyclosporin A, etretinate, acitretin, PUVA, fumaric acid) three months prior to screening
  • Volunteers who were treated with any systemic (oral, intramuscular, high-dose inhaled, rectal) 4 weeks prior to screening
  • Volunteers who were treated with any local therapy for psoriasis (e.g. corticosteroids, calcitriol analogues, dithranol, phototherapy) 2 weeks prior to screening
  • Target plaques localized on head and neck, elbows and knees, palms and soles, nails and folds or other mechanically strained sites
  • Volunteers with guttate or pustular psoriasis
  • Volunteers with spontaneously improving or rapidly deteriorating plaque-type psoriasis
  • Volunteers with erythrodermic type of psoriasis
  • Volunteers with severe recalcitrant psoriasis requiring additional therapy
  • Presence of virus surface antigen, virus antibodies or human immune deficiency virus antibodies
  • Clinico-chemical parameters of deviation
  • Volunteers with a known allergy to any of the of the trial medication
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Mapracorat

    10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2

    Drug: Mapracorat (ZK 245186, BAY 86-5319)

  • Active comparator
    Prednicarbate

    10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2

    Drug: Prednicarbate 0.25% ointment

  • Active comparator
    Clobetasol

    10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2

    Drug: Clobetasol 0.05% ointment

  • Active comparator
    Calcipotriene

    10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2

    Drug: Calcipotriene 0.005% ointment

  • Active comparator
    Calcipotriene/Betamethasone dipropionate

    10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2

    Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment

Interventions

  • 0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment

  • DrugPrednicarbate 0.25% ointment

    0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment

  • 0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment

  • 0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment

  • DrugCalcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment

    Drug page: Calcipotriene

    0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment

06

What researchers measure

Primary outcomes

  1. Baseline-corrected area under the curve of the psoriatic infiltrate thickness (PIT) measured by 20 MHz B mode ultrasound

    Assessment was done on the test fields on psoriatic plaques

    Time frame: Prior to drug application from Day 1 and up to Day 29

Secondary outcomes

  1. Skin thickness measurement of occluded test field on non-lesional skin (mean of triplicate measurement)

    Assessment was made on occluded test fields on non-lesional skin areas on the forearm

    Time frame: Prior to drug application from Day 1 up to Day 60

  2. Clinical assessment of atrophy using a 5-point score

    Assessment was made on occluded test fields on non-lesional skin areas on the forearm

    Time frame: Prior to drug application from Day 1 and up to Day 29

  3. Clinical assessment of telangiectasia using a 5-point score

    Assessment was made on occluded test fields on non-lesional skin areas on the forearm

    Time frame: Prior to drug application from Day 1 and up to Day 29

  4. Clinical assessment of local tolerability using a 5-point score

    Assessment was made on occluded test fields on non-lesional skin areas on the forearm

    Time frame: Prior to drug application from Day 1 and up to Day 29

  5. PIT measured by 20 MHz B mode ultrasound

    Assessment was done on the test fields on psoriatic plaques

    Time frame: Prior to drug application from Day 1 and up to Day 29

  6. Measurement of erythema using chromametry (mean of triplicate measurement)

    Assessment was done on the test fields on psoriatic plaques

    Time frame: Prior to drug application from Day 1 and up to Day 29

  7. Clinical efficacy assessment of the skin in the test fields using a 5-point score

    Assessment was done on the test fields on psoriatic plaques

    Time frame: Prior to drug application from Day 1 and up to Day 29

  8. Number of participants with adverse events

    Time frame: Approximately 64-84 days

07

Study locations

1 site
  • Hamburg, 20095, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in May 2013, 3 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 16, 2018
StartActual
Feb 11, 2013
Primary completionActual
May 31, 2013
CompletionActual
May 31, 2013
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399526
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
Feb 11, 2013
Primary completion
May 31, 2013
Completion
May 31, 2013
Last update
Jan 16, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mapracorat

Start the discussion